Unicycive Therapeutics Inc (UNCY) - Total Assets
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) holds total assets worth $49.13 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net asset quality index of Unicycive Therapeutics Inc to measure how much of total assets are equity-financed.
Unicycive Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Unicycive Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check Unicycive Therapeutics Inc (UNCY) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Unicycive Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Unicycive Therapeutics Inc's total assets of $49.13 Million consist of 99.7% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 59.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Unicycive Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Unicycive Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Unicycive Therapeutics Inc's current assets represent 99.7% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 59.4% of total assets in 2025, down from 86.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Unicycive Therapeutics Inc Competitors by Total Assets
Key competitors of Unicycive Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Unicycive Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.59 | 1.28 | 0.13 |
| Quick Ratio | 2.59 | 1.28 | 0.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $30.02 Million | $6.83 Million | $-3.40 Million |
Unicycive Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Unicycive Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.01 |
| Latest Market Cap to Assets Ratio | 3.83 |
| Asset Growth Rate (YoY) | 55.2% |
| Total Assets | $49.13 Million |
| Market Capitalization | $188.24 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Unicycive Therapeutics Inc's assets at a significant premium (3.83x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Unicycive Therapeutics Inc's assets grew by 55.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Unicycive Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Unicycive Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $49.13 Million | +55.16% |
| 2024-12-31 | $31.67 Million | +123.16% |
| 2023-12-31 | $14.19 Million | +403.58% |
| 2022-12-31 | $2.82 Million | -84.97% |
| 2021-12-31 | $18.74 Million | +9088.24% |
| 2020-12-31 | $204.00K | +973.68% |
| 2019-12-31 | $19.00K | -34.48% |
| 2018-12-31 | $29.00K | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more